237 related articles for article (PubMed ID: 30107134)
1. Glucocorticoid-induced TNFR-related gene (GITR) as a therapeutic target for immunotherapy.
Riccardi C; Ronchetti S; Nocentini G
Expert Opin Ther Targets; 2018 Sep; 22(9):783-797. PubMed ID: 30107134
[TBL] [Abstract][Full Text] [Related]
2. GITR ligand fusion protein agonist enhances the tumor antigen-specific CD8 T-cell response and leads to long-lasting memory.
Durham NM; Holoweckyj N; MacGill RS; McGlinchey K; Leow CC; Robbins SH
J Immunother Cancer; 2017; 5():47. PubMed ID: 28649380
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological modulation of GITRL/GITR system: therapeutic perspectives.
Nocentini G; Ronchetti S; Petrillo MG; Riccardi C
Br J Pharmacol; 2012 Apr; 165(7):2089-99. PubMed ID: 22029729
[TBL] [Abstract][Full Text] [Related]
4. The Role of GITR/GITRL Interaction in Autoimmune Diseases.
Tian J; Zhang B; Rui K; Wang S
Front Immunol; 2020; 11():588682. PubMed ID: 33163004
[TBL] [Abstract][Full Text] [Related]
5. GITR: a modulator of immune response and inflammation.
Nocentini G; Riccardi C
Adv Exp Med Biol; 2009; 647():156-73. PubMed ID: 19760073
[TBL] [Abstract][Full Text] [Related]
6. T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy.
Snell LM; Lin GH; McPherson AJ; Moraes TJ; Watts TH
Immunol Rev; 2011 Nov; 244(1):197-217. PubMed ID: 22017440
[TBL] [Abstract][Full Text] [Related]
7. GITR-GITRL system, a novel player in shock and inflammation.
Krausz LT; Bianchini R; Ronchetti S; Fettucciari K; Nocentini G; Riccardi C
ScientificWorldJournal; 2007 May; 7():533-66. PubMed ID: 17525820
[TBL] [Abstract][Full Text] [Related]
8. Rationale for anti-GITR cancer immunotherapy.
Knee DA; Hewes B; Brogdon JL
Eur J Cancer; 2016 Nov; 67():1-10. PubMed ID: 27591414
[TBL] [Abstract][Full Text] [Related]
9. Glucocorticoid-induced tumor necrosis factor receptor family-related ligand triggering upregulates vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 and promotes leukocyte adhesion.
Lacal PM; Petrillo MG; Ruffini F; Muzi A; Bianchini R; Ronchetti S; Migliorati G; Riccardi C; Graziani G; Nocentini G
J Pharmacol Exp Ther; 2013 Oct; 347(1):164-72. PubMed ID: 23892569
[TBL] [Abstract][Full Text] [Related]
10. Authentic GITR Signaling Fails To Induce Tumor Regression unless Foxp3+ Regulatory T Cells Are Depleted.
Kim YH; Shin SM; Choi BK; Oh HS; Kim CH; Lee SJ; Kim KH; Lee DG; Park SH; Kwon BS
J Immunol; 2015 Nov; 195(10):4721-9. PubMed ID: 26423152
[TBL] [Abstract][Full Text] [Related]
11. Role of the glucocorticoid-induced TNFR-related protein (GITR)-GITR ligand pathway in innate and adaptive immunity.
Azuma M
Crit Rev Immunol; 2010; 30(6):547-57. PubMed ID: 21175417
[TBL] [Abstract][Full Text] [Related]
12. Modulation of tumor immunity: a patent evaluation of WO2015026684A1.
Nocentini G; Cari L; Ronchetti S; Riccardi C
Expert Opin Ther Pat; 2016; 26(3):417-25. PubMed ID: 26560753
[TBL] [Abstract][Full Text] [Related]
13. Cell-specific and context-dependent effects of GITR in cancer, autoimmunity, and infection.
Clouthier DL; Watts TH
Cytokine Growth Factor Rev; 2014 Apr; 25(2):91-106. PubMed ID: 24484736
[TBL] [Abstract][Full Text] [Related]
14. GITR+ regulatory T cells in the treatment of autoimmune diseases.
Petrillo MG; Ronchetti S; Ricci E; Alunno A; Gerli R; Nocentini G; Riccardi C
Autoimmun Rev; 2015 Feb; 14(2):117-26. PubMed ID: 25449679
[TBL] [Abstract][Full Text] [Related]
15. Anti-glucocorticoid-induced Tumor Necrosis Factor-Related Protein (GITR) Therapy Overcomes Radiation-Induced Treg Immunosuppression and Drives Abscopal Effects.
Schoenhals JE; Cushman TR; Barsoumian HB; Li A; Cadena AP; Niknam S; Younes AI; Caetano MDS; Cortez MA; Welsh JW
Front Immunol; 2018; 9():2170. PubMed ID: 30294332
[TBL] [Abstract][Full Text] [Related]
16. Enhanced CD8 T cell responses through GITR-mediated costimulation resolve chronic viral infection.
Pascutti MF; Geerman S; Slot E; van Gisbergen KP; Boon L; Arens R; van Lier RA; Wolkers MC; Nolte MA
PLoS Pathog; 2015 Mar; 11(3):e1004675. PubMed ID: 25738498
[TBL] [Abstract][Full Text] [Related]
17. Synergistic antitumor responses by combined GITR activation and sunitinib in metastatic renal cell carcinoma.
Yu N; Fu S; Xu Z; Liu Y; Hao J; Zhang A; Wang B
Int J Cancer; 2016 Jan; 138(2):451-62. PubMed ID: 26239999
[TBL] [Abstract][Full Text] [Related]
18. Dual Roles for Regulatory T-cell Depletion and Costimulatory Signaling in Agonistic GITR Targeting for Tumor Immunotherapy.
Mahne AE; Mauze S; Joyce-Shaikh B; Xia J; Bowman EP; Beebe AM; Cua DJ; Jain R
Cancer Res; 2017 Mar; 77(5):1108-1118. PubMed ID: 28122327
[TBL] [Abstract][Full Text] [Related]
19. Rational design of anti-GITR-based combination immunotherapy.
Zappasodi R; Sirard C; Li Y; Budhu S; Abu-Akeel M; Liu C; Yang X; Zhong H; Newman W; Qi J; Wong P; Schaer D; Koon H; Velcheti V; Hellmann MD; Postow MA; Callahan MK; Wolchok JD; Merghoub T
Nat Med; 2019 May; 25(5):759-766. PubMed ID: 31036879
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cells combined with anti-GITR antibody produce antitumor effects in osteosarcoma.
Kawano M; Tanaka K; Itonaga I; Iwasaki T; Miyazaki M; Ikeda S; Tsumura H
Oncol Rep; 2015 Oct; 34(4):1995-2001. PubMed ID: 26239052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
